<DOC>
	<DOCNO>NCT01012869</DOCNO>
	<brief_summary>Chronically total occlusion ( CTO ) difficult treat high risk restenosis . Although everolimus-eluting stent ( EES ) [ ( Xience , Abbott Vascular ) Promus ( Boston Scientific ) ] promise treatment CTOs due low late loss excellent deliverability , currently publish data EES implantation CTOs . The specific aim proposal examine 8-month incidence binary angiographic in-stent restenosis ( defined stenosis &gt; 50 % minimum lumen diameter target stent ) implantation EES CTO . It investigators hypothesis EES-treated CTO lesion â‰¤ 20 % 8-month in-stent binary angiographic restenosis rate .</brief_summary>
	<brief_title>AngiographiC Evaluation Everolimus-Eluting Stent Chronic Total Occlusions - ACE-CTO Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Age &gt; 18 year old 2 . Successful treatment native coronary artery CTO ( define lesion 100 % angiographic stenosis least 3 month old estimate clinical information , sequential angiographic information , ) use everolimuseluting stent 3 . Able willing return angiographic followup 8 month follow clinically 12 month 4 . Agree participate provide inform consent 1 . Planned noncardiac surgery within follow 12 month 2 . Recent positive pregnancy test , breastfeeding , possibility future pregnancy 3 . Coexisting condition limit life expectancy le 12 month 4 . Patients creatinine 2.5 mg/dL ( unless require hemodialysis , case eligible participate ) 5 . History allergic reaction significant sensitivity everolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Coronary chronic total occlusion</keyword>
</DOC>